Get started
Author

Viraj Degaonkar

Observed name: V. Degaonkar
ORCID: 0009-0009-4992-7599
Observed ORCID: 0009-0009-4992-7599
OpenAlex ID: A5083226225
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
2021 · Thomas Powles, Zoe June Assaf, et al. · Nature · 695
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
2021 · Joaquim Bellmunt, Maha Hussain, et al. · The Lancet Oncology · 463
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
2025 · Thomas Powles, Ariel G. Kann, et al. · New England Journal of Medicine · 224
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma
2023 · Thomas Powles, Zoe June Assaf, et al. · European Urology · 181
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma
2020 · Alexandra Drakaki, Preet K Dhillon, et al. · OncoImmunology · 67
PDF
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
2024 · Habib Hamidi, Yasin Senbabaoglu, et al. · Cancer Cell · 62
IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
2020 · Maha H. A. Hussain, Thomas Powles, et al. · Journal of Clinical Oncology · 51
“Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma
2020 · Alexandra Drakaki, Allan Pantuck, et al. · Urologic Oncology Seminars and Original Investigations · 26
PDF
1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy
2020 · T.B. Powles, Z.J. Assaf, et al. · Annals of Oncology · 24
PDF
Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice
2019 · A. Drakaki, P. Luhn, et al. · Annals of Oncology · 19
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors
2024 · Daniel R. Zollinger, Elizabeth Rivers, et al. · PLoS ONE · 14
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay
2023 · Thomas Powles, Amanda Young, et al. · Frontiers in Oncology · 14
PDF
716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy
2021 · T.B. Powles, J.E. Gschwend, et al. · Annals of Oncology · 14
PDF
Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC.
2020 · Alexandra Drakaki, Arash Rezazadeh Kalebasty, et al. · Journal of Clinical Oncology · 14
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
2025 · Jacqueline H. Starrett, Eric L. Allen, et al. · Molecular Cancer Therapeutics · 3
Disease-free Survival and Overall Survival in Patients With High-risk Muscle-invasive Bladder Cancer Who Have Persistent Circulating Tumor Dna-negative Biomarker Status Post-cystectomy: Imvigor011 Study Surveillance Analysis
2025 · Joaquim Bellmunt, Jürgen E. Gschwend, et al. · Urologic Oncology Seminars and Original Investigations · 2
ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial.
2026 · Andrew J. Murtha, Valentina Boni, et al. · Journal of Clinical Oncology · 1
PDF
IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab
2022 · T. Powles, Z. June Assaf, et al. · European Urology Open Science · 1
IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC)
2017 · J. Gschwend, J. Bellmunt, et al. · European Urology Supplements · 1
Supplementary Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
2026 · Jacqueline H. Starrett, Eric L. Allen, et al.
Figure 2 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
2026 · Jacqueline H. Starrett, Eric L. Allen, et al.
Figure 1 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
2026 · Jacqueline H. Starrett, Eric L. Allen, et al.
Figure 3 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
2026 · Jacqueline H. Starrett, Eric L. Allen, et al.
Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
2026 · Jacqueline H. Starrett, Eric L. Allen, et al.
Figure 4 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
2026 · Jacqueline H. Starrett, Eric L. Allen, et al.
Works count: 32
Citation count: 1,876
H-index: 14
I10-index: 14
Year
Topic
Type